Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study by Opstal-van Winden, Annemieke WJ et al.
RESEARCH ARTICLE Open Access
Searching for early breast cancer biomarkers by
serum protein profiling of pre-diagnostic serum;
a nested case-control study
Annemieke WJ Opstal-van Winden
1,2, Esmeralda JM Krop
3, Monica H Kåredal
4, Marie-Christine W Gast
2,5,
Christian H Lindh
4, Marina C Jeppsson
4, Bo AG Jönsson
4, Diederick E Grobbee
1, Petra HM Peeters
1,6,
Jos H Beijnen
2,7, Carla H van Gils
1*† and Roel CH Vermeulen
1,3†
Abstract
Background: Serum protein profiles have been investigated frequently to discover early biomarkers for breast
cancer. So far, these studies used biological samples collected at or after diagnosis. This may limit these studies’
value in the search for cancer biomarkers because of the often advanced tumor stage, and consequently risk of
reverse causality. We present for the first time pre-diagnostic serum protein profiles in relation to breast cancer,
using the Prospect-EPIC (European Prospective Investigation into Cancer and nutrition) cohort.
Methods: In a nested case-control design we compared 68 women diagnosed with breast cancer within three
years after enrollment, with 68 matched controls for differences in serum protein profiles. All samples were
analyzed with SELDI-TOF MS (surface enhanced laser desorption/ionization time-of-flight mass spectrometry). In a
subset of 20 case-control pairs, the serum proteome was identified and relatively quantified using isobaric Tags for
Relative and Absolute Quantification (iTRAQ) and online two-dimensional nano-liquid chromatography coupled
with tandem MS (2D-nanoLC-MS/MS).
Results: Two SELDI-TOF MS peaks with m/z 3323 and 8939, which probably represent doubly charged
apolipoprotein C-I and C3a des-arginine anaphylatoxin (C3adesArg), were higher in pre-diagnostic breast cancer
serum (p = 0.02 and p = 0.06, respectively). With 2D-nanoLC-MS/MS, afamin, apolipoprotein E and isoform 1 of
inter-alpha trypsin inhibitor heavy chain H4 (ITIH4) were found to be higher in pre-diagnostic breast cancer (p <
0.05), while alpha-2-macroglobulin and ceruloplasmin were lower (p < 0.05). C3adesArg and ITIH4 have previously
been related to the presence of symptomatic and/or mammographically detectable breast cancer.
Conclusions: We show that serum protein profiles are already altered up to three years before breast cancer
detection.
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Background
Early diagnosis of breast cancer by mammography is
one of the most important factors contributing to the
successful treatment of breast cancer. Further improve-
ment of early diagnosis might be possible with the use
of blood-based biomarkers. Such markers could indicate
the presence of a breast tumour already in an early
stage, preferably even before the lesion is visual on a
mammogram. This would be particularly relevant for
young women for whom mammographic screening is
less effective due to lower sensitivity (25 to 59%) [1].
Although the addition of magnetic resonance imaging
(MRI) to mammography could improve sensitivity [1], a
blood test would be less expensive and easier to perform
on a large scale.
Many studies have been executed in an attempt to
find such early breast cancer biomarkers, for example
using surface enhanced laser desorption/ionization
* Correspondence: C.vanGils@umcutrecht.nl
† Contributed equally
1Julius Center for Health Sciences and Primary Care, University Medical
Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
Opstal-van Winden et al. BMC Cancer 2011, 11:381
http://www.biomedcentral.com/1471-2407/11/381
© 2011 Opstal-van Winden et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.time-of-flight mass spectrometry (SELDI-TOF MS)
[2-9]. Several proteins in the blood were indeed found
to be related to the presence of breast cancer [2-9].
However, only few of these proteins were reported to
be discriminative for breast cancer in more than one
study, and even then, some proteins found to be
higher in patients in one study, were found to be
lower in another study [2-9]. These discrepancies may
be caused by differences between cases and controls in
collection, processing and storage of their blood sam-
ples, both within and between studies [10-16]. On the
other hand, it cannot be excluded that findings were
simply due to chance.
Until now, all studies, except one by Pitteri et al.
[17], used biological samples collected at or after diag-
nosis of breast cancer, and thus findings may reflect
consequences rather than predictors of malignancy.
Thus, it remains unclear whether these proteins are
able to identify women with a breast lesion which is
not yet visible on a mammogram and does not induce
clinical symptoms yet. Pitteri et al. [17] previously
investigated plasma samples prospectively collected in
the Women’s Health Initiative Observational Study.
Epidermal Growth Factor Receptor (EGFR) was found
to be increased in plasma samples collected 17 months
before breast cancer diagnosis. In the present study we
performed serum protein profiling of breast cancer
samples for the first time in a nested case-control
study. For this we used the Prospect-EPIC (European
Prospective Investigation into Cancer and nutrition)
cohort [18], where at study enrollment blood samples
of approximately 17,000 healthy women were collected
and stored. For the current study we selected those
women who were diagnosed with breast cancer within
3 years after enrollment in the cohort. Pre-diagnostic
protein profiles of their serum samples, taken at
enrollment, were compared to those of matched con-
trols who remained healthy.
Our first aim was to assess whether previously
reported proteins are also discriminative in serum sam-
ples taken up to three years before breast cancer diagno-
sis. We also set out to discover new discriminating
proteins. To this end, we used SELDI-TOF MS that has
the possibility to measure multiple proteins simulta-
neously in a high-throughput fashion. Next, in a subset
of the case-control pairs, we analyzed the serum protein
profiles with isobaric Tags for Relative and Absolute
Quantification (iTRAQ)-labeling, and two-dimensional
online nano-liquid chromatography coupled with tan-
dem mass spectrometry (2D-nanoLC-MS/MS), by which
the detected proteins are relatively quantified and imme-
diately identified. SELDI-TOF MS and 2D-nanoLC-MS/
MS cover different mass ranges and therefore are able
to detect different proteins.
In summary, we set out to find new proteins as well as
to test previously detected proteins in patients still free
of symptomatic breast cancer.
Methods
Study population
We performed a case-control study nested within the
Prospect-EPIC cohort. Prospect-EPIC is one of the two
Dutch cohorts participating in the European Prospective
Investigation into Cancer and nutrition, which includes
ten European countries. From 1993 to 1997, 17,357
women from Utrecht and vicinity, aged 50-69 years,
enrolled in this cohort through the national population-
based breast cancer screening program [18]. Women
filled out an extensive food frequency questionnaire and
a general questionnaire. The latter contained questions
on demographic characteristics, medical history, lifestyle
characteristics, and risk factors for cancer and other
chronic diseases [18,19].
Prospect-EPIC participants also donated a blood sam-
ple. Blood collection, processing and storage were per-
formed following a strict protocol. After collection,
blood samples were stored in a climate controlled refrig-
erator at 5°C overnight. The next day blood samples
were centrifuged at 1500 g for 20 minutes. After centri-
fuging, the serum was put in 0.5 ml straws. These straws
were stored in a -86°C freezer until they were trans-
ported to liquid nitrogen tanks (-196°C), where they
have been stored since then.
Participants were followed for vital and health status.
Information on dates of death and migration was
obtained through the municipal registries. Causes of
death were obtained from the Central Bureau for Statis-
tics (CBS). Through yearly linkage with the regional and
national cancer registries information about cancer inci-
dence and stage of disease at diagnosis (tumor behavior,
tumor size, lymph node involvement and metastasis)
was obtained [18]. Until December 31
st 2006, 687
women were diagnosed with breast cancer in the Pro-
spect-EPIC cohort. All participants signed an informed
consent and the study was approved by the Institutional
Review Board of the University Medical Center Utrecht.
F o rt h ec u r r e n ts t u d yw es e l e c t e dw o m e nw h ow e r e
diagnosed with breast cancer within three years after
enrollment into the cohort, and who were postmeno-
pausal at enrollment (no menstrual periods in last 12
months). Women were excluded if they had had cancer
before, were suffering from diabetes, were current smo-
kers, or were currently using oral contraceptives, or
menopausal hormone therapy (HT). This was done to
obtain a homogeneous group with respect to hormone
levels, smoking status, and metabolic status, because
these factors (may) influence serum protein profiles
[20]. Sixty-eight women weree v e n t u a l l yi n c l u d e da sa
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matched each case with one postmenopausal control
that remained free of breast cancer up to the time the
case was diagnosed. Additional matching factors were
age at enrollment (± 1 year) and date of enrollment (±
1/2 year). For controls the same exclusion criteria were
applied as for cases. Differences between cases and con-
trols, and between samples of cases and controls, were
tested with independent samples T test for normally dis-
tributed continuous variables, with Mann-Whitney U
test for other continuous variables, and Pearson Chi-
Square for categorical variables.
SELDI-TOF MS analysis
We performed serum protein profiling on immobilized
metal affinity capture (IMAC30) ProteinChip arrays
(Bio-Rad Labs, Hercules, Ca, USA) activated with nickel
as described in our previous study [9]. The total sample
set was analyzed in duplicate, in three separate batches,
within two weeks time. Duplicates were analyzed within
the same batch, but on different arrays, to correct for
inter-array variability. Cases and controls were evenly,
and randomly, distributed over the three batches. Sam-
ples in one batch were prepared and applied to the
arrays, followed by detection of the proteins bound to
the arrays with SELDI-TOF MS, on the same day.
SELDI-TOF MS was performed using the PBS-IIC Pro-
teinChip Reader (Bio-Rad Labs). See Additional file 1
for settings of the ProteinChip Reader.
Since analyzing samples in different batches, on differ-
ent days, introduces inter-batch variation [16,21,22],
spectra were processed per batch. For this, we used the
ProteinChip Software package, version 3.1 (Bio-Rad
Labs). Spectra in which normalization revealed too low
or too high total ion current were excluded from further
analysis. The cases and controls matched with these
subjects were also excluded from the paired analyses.
Subsequently, the Biomarker Wizard (BMW) software
application (Bio-Rad Labs) was used to detect peaks.
This was performed in each batch separately. See Addi-
tional file 1 for way of processing the spectra and for
the settings for peak detection.
SELDI-TOF MS data analysis
Peak information from all acquired spectra was exported
from the ProteinChip Software to SPSS 15.0 for statisti-
cal analysis. First, we estimated the reproducibility of
the duplicates, by calculating the median coefficient of
variance (CV) for each detected peak, in cases and con-
trols together. The averaged intensities of the peaks
with the same mass in the duplicate spectra of a subject
were used for further analysis. To be able to merge peak
intensity data of the three batches, averaged peak inten-
sities were first Z-log-transformed per batch [23].
Paired samples T tests were used to test if the mean
Z-log-transformed peak intensities in the pre-diagnostic
breast cancer serum samples were statistically signifi-
cantly different from those in the controls samples. We
performed correction for multiple testing, using the
False Discovery Rate (FDR) method suggested by Benja-
min and Hochberg. The FDR controls the expected pro-
portion of falsely rejected hypothesis [24]. We chose
10% as an acceptable proportion of false positive results
(q-value = 0.10). We also investigated whether any sig-
nificant relation could be explained by any of the subject
characteristics other than breast cancer status. To this
end, bivariate conditional logistic regression analyses
were performed including the peak intensity (continu-
ous) and one of the following characteristics: Body Mass
Index (BMI), former use of oral contraceptives, former
use of HT, number of children, smoking habits, alcohol
consumption, blood sample’s time in refrigerator
between blood collection and centrifugation, and sam-
ple’s time in -86°C freezer until storage at liquid nitro-
gen. The adjusted odds ratios (OR) resulting from the
analyses were compared with the crude breast cancer
OR in relation to peak intensity. To test whether the
intensities of peaks that differed between cases and con-
trols, also differed between cases that were more close
to diagnosis, and cases that were less close to diagnosis
at moment of sample collection, we performed indepen-
dent sample T tests. To this end, cases who were diag-
nosed based on the first mammogram after enrollment
were compared to cases who had a negative first mam-
mogram and who were diagnosed at a later moment.
Sample preparation for 2D-nanoLC-MS/MS
We restricted the 2D-nanoLC-MS/MS analysis to 20
case-control pairs, because of costs and time restric-
tions. The cases included in this sub-analysis were diag-
nosed with breast cancer within the first 14 months
after enrollment in the study.
The serum samples were depleted of the high abun-
dant proteins albumin, IgG, antitrypsin, IgA, transferrin
and haptoglobin, using the Multiple Affinity Removal
Spin Cartridge (Hu-6HC, Agilent Technologies, Santa
Clara, CA, USA) as described in the manufacturer’s pro-
tocol. Thereafter the samples were desalted using
Microcon Centrifugal Filter units (Millipore, Billerica,
MA. USA). The total protein content of the depleted
sera was determined using a protein assay kit (BCA™,
Pierce, Thermo Scientific, Rockfort, IL, USA). The pro-
teins (50 μg per sample) were reduced using tris(2-car-
boxyethyl)phosphine, alkylated using iodoacetamide and
then trypsin digested (Roche Diagnostics Gmbh, Man-
nhein, Germany) overnight and evaporated to dryness
using a SpeedVac. Peptides were labeled with 4-plex
iTRAQ reagents (iTRAQ reagent kit-plasma, Applied
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instructions of the manufacturer.
Two case-control pairs were labeled with different iso-
baric tags in each iTRAQ-labeling set. The first case was
labeled with tag114 and the matching control with
tag115, the next case was labeled with tag116 and the
matching control with tag117. The 4 labeled samples
were finally pooled into a new sample tube. A total of
10 iTRAQ-labeled sample sets consisting of two case-
control pairs were generated.
2D-nanoLC-MS/MS analysis
The 10 iTRAQ-labeled sample sets were analyzed using
quadrupole-time-of-flight mass spectrometer (QSTAR
pulsar; Applied Biosystems), equipped with a nanoelec-
trospray source (Proxeon, Odense, Denmark), and con-
nected to a 2D-nanoLC system equipped with a
capillary and nano pump (1100 series; Agilent Technol-
ogies). See Additional file 2 for details about the used
columns and mobile phases. The LC system was
coupled on-line to a fused-silica PicoTip (50 μmi . d .×
360 μmo . d .×8μm tip; New Objective, Woburn, MA,
USA). Details about acquisition and calibration are also
described in Additional file 2.
2D-nanoLC-MS/MS data analysis
Protein identifications and quantifications were per-
formed using Protein Pilot 1.0 (Applied Biosystems) in
which the paragon search algorithm was applied. Pro-
teins were searched against the IPI human protein data-
base (IPI human v3.40) downloaded from http://www.
ebi.ac.uk[25]. See Additional file 3 for details on search
parameters and data processing.
In some runs, some peptides were unusable for quan-
tification due to an artificial low signal of the signature
ions or because the peptide sequence was shared by
other proteins. In those cases the peptides were
excluded from quantification. No iTRAQ ratio was cal-
culated if there was not one usable peptide left. If only
one peptide was usable for quantification of a protein
then no error factor (EF) was calculated. A case-control
pair was excluded when no ratio and/or EF could be
calculated for this pair. Only proteins that could be
measured in at least 14 of the 20 case-control pairs
were selected for further analysis.
The ratios and the EFs for a protein, in the different
pairs, were used to model a random effect model. We
used the random effect model since we assumed hetero-
geneity between the ratios of the different pairs that is
partly based on variation by coincidence, but also on
true variation between the pairs. The random effect
model resulted in a weighted mean ratio with a 95%
confidence interval (95%CI) for every protein. We also
applied correction for multiple testing using de FDR
method on these results. We again choose 10% as an
acceptable proportion of false positive results.
Results
Study population
Characteristics of the total study population are pre-
sented in Table 1. About half of both cases and controls
used oral contraceptives in the past, but the cases used
them for a longer period of time than the controls
(median: 10 years and 4.5 years, respectively; p-value
0.018). Cases were somewhat more often nulliparous
(15%) than controls (7%), and among women with chil-
dren, controls had more children than the cases; 3 and
2 (median), respectively, although not statistically signifi-
cantly. About half of both cases and controls had
smoked in the past, for about 8 and 4 pack-years (med-
ian), respectively (p = 0.187). Characteristics of the
serum samples and the sample collection are listed in
Table 2. There was no difference between cases and
controls regarding sample collection and storage. Char-
acteristics of the subjects in the subset (analyzed by 2D-
nanoLC-MS/MS), and of their serum samples, are
shown in Additional file 4 and 5.
Breast cancer was diagnosed after a median time of
21.3 months (inter-quartile range (IQR): 0.7-26.6) after
enrollment. More than 80% of the cases had an invasive
tumor. More than half of the invasive tumors were diag-
nosed in Stage I and a quarter of the invasive tumors
were diagnosed in Stage IIA. Only one tumor was diag-
nosed in Stage IIIA. The invasive tumors were more or
less equally distributed over the three size categories
(>0.1-1 cm, 1-2 cm and >2 cm). In almost 30% of the
invasive tumors, lymph nodes were involved. None of
the cases was diagnosed with distant metastasis. We
reported the pathologically determined tumor size and
lymph node involvement unless this was unknown; in
that case we reported the clinically determined stage.
Cases in the subset analyzed by 2D-nanoLC-MS/MS
were diagnosed 0.9 months (median) (IQR: 0.6-7.5) after
enrollment. Two of the 20 cases were diagnosed with
carcinoma in situ. Two thirds of the invasive tumors
were diagnosed in Stage I and almost a quarter in Stage
IIA, the remaining tumors were diagnosed in Stage IIB.
Half of the invasive tumors were sized <1 cm, and in
only three invasive tumors lymph nodes were involved.
Peaks detected with SELDI-TOF MS
After normalization, 25 of the 272 spectra (68 cases and
68 controls in duplicate) had to be eliminated from the
analysis. These outliers included 12 spectra of cases and
13 spectra of controls. Of one case and two controls
both spectra (duplicates) had to be eliminated. With the
BMW software application, in total 47 different peaks
were auto-detected in the three batches. Twenty-two of
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of the spectra in each batch. The median CV’so ft h e s e
peaks varied between 12% and 35%.
The intensity of a peak with mass-to-charge ratio (m/
z) 3323 was statistically significantly higher in pre-diag-
nostic breast cancer serum samples than in serum sam-
ples of controls (p = 0.02). The intensity of a peak with
m/z 8938 was borderline statistically significantly higher
in cases than in controls (p = 0.06) (Figure 1). No statis-
tically significant relations were found between the
intensities of the other detected peaks and the early
presence of breast cancer. Correction for multiple test-
ing revealed that none of the detected peaks had less
than 10% chance to be a false positive finding. The 22
detected peaks ordered by their m/z, together with their
mean Z-log-transformed peak intensities in cases and
controls, and the results of the paired T test are listed
in Table 3.
Bivariate conditional logistic regression analysis
revealed that the relations between m/z 3323 and breast
cancer, and m/z 8938 and breast cancer, were indepen-
dent of BMI, oral contraceptives use, HT use, number
Table 1 Study population characteristics
Cases
(n = 68)
Controls
(n = 68)
P-value
††
Age at enrollment (years)
Mean (SD) 60.2 (5.6) 60.3 (5.7) 0.966
BMI
Mean (SD) 26.6 (3.1) 26.3 (3.6) 0.603
Missing 1 -
Use of oral contraceptives, n (%)
No, but used to in the past 36 (52.9) 40 (58.8) 0.490
No, never 32 (47.1) 28 (41.2)
Duration of oral contraceptives use* (years)
Median (IQR) 10.0 (4.3-15.8) 4.5 (2.0-10.0) 0.018
Use of HT, n (%)
No, but used to in the past 7 (10.3) 6 (8.8) 0.771
No, never 61 (89.7) 62 (91.2)
Duration of HT use* (years)
Median (IQR) 1.0 (1.0-8.0) 2.0 (1.0-10.0) 0.273
Ovariectomy, n (%)
Both ovaries removed 5 (7.4) 3 (4.5) 0.479
Missing - 1
Parity, n (%)
Nulliparous 10 (14.7) 5 (7.4) 0.171
Number of children
†
Median (IQR) 2.0 (2.0-3.0) 3.0 (2.0-3.0) 0.100
Smoking, n (%)
No, but used to in the past 31 (45.6) 34 (50.0) 0.607
No, never 37 (54.4) 34 (50.0)
Pack-years smoking until stop date
‡
Median (IQR) 7.9 (1.9-16.4) 4.1 (1.4-10.2) 0.187
Missing 1 3
Alcohol intake (g/day)
§
Median (IQR) 2.0 (0.2-7.2) 2.5 (0.2-8.4) 0.638
Use of medicines, minerals or vitamins
#, n (%)
Yes 46 (67.6) 44 (64.7)
No 22 (32.4) 24 (35.3) 0.717
Time since last meal and/or drink** (min)
Median (IQR) 108 (87-137) 116 (88-137) 0.651
SD: standard deviation; BMI: body mass index; IQR: inter-quartile range; HT: menopausal hormone therapy; * Among former oral contraceptives/HT users;
†
Among women with children;
‡ Among former smokers;
§ Energy-adjusted alcohol intake at enrollment;
# In last week before blood collection; ** At moment of
blood collection;
†† Independent samples T test for age and BMI, Mann-Whitney U test for other continuous variables, and Pearson Chi-Square test for categorical
variables.
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blood sample in refrigerator between collection and cen-
trifugation, or serum sample storage duration at -86°C
before storage at liquid nitrogen (data not shown).
Twenty-three cases were diagnosed based on the first
screening after enrollment, 43 cases had a negative
mammogram at first screening and were diagnosed at a
later moment. The mean Z-log-transformed intensity of
m/z 3323 was not different between the early breast
cancer cases and the very early breast cancer cases (0.22
(SD:0.96) and 0.21 (SD:1.00), respectively; p = 0,99). The
mean Z-log-transformed intensity of m/z 8938 was
somewhat higher in the early breast cancer cases, com-
pared to the very early breast cancer cases, although not
statistically significantly (0.23 (SD:0.86) and 0.16
(SD:1.11), respectively; p = 0.79).
Identities of the SELDI-TOF MS peaks
Based on results of a previous study performed by our
group [26], the peak with m/z 3323 is likely to be dou-
bly charged apolipoprotein C-I. We previously identified
a 6.6 kDa peak as apolipoprotein C-I (molecular weight
Figure 1 Difference in protein expression of m/z 3323 and m/z 8938, detected with SELDI-TOF MS, between breast cancer cases and
healthy controls.
Table 2 Characteristics of the serum samples
Cases
(n = 68)
Controls
(n = 68)
P-
value
Serum sample storage duration*
(years)
Mean (SD) 11.2 (1.1) 11.2 (1.1) 0.900
§
Hours in refrigerator
†
Median (IQR) 22 (21-
23)
22 (20-
23)
0.845
#
Days at -86°C
‡
Median (IQR) 8 (6-11) 7 (5-11) 0.429
#
SD: standard deviation; IQR: inter-quartile range; * Until date of experiment;
†
Between collection and centrifugation;
‡ Between centrifugation and storage
at liquid nitrogen;
§ Independent samples T test;
# Mann-Whitney U test.
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digestion and peptide mapping. Its identity was con-
firmed with an immunoassay. In the same study, a
highly correlated 3.3 kDa peak was found to be the
result of double charged apolipoprotein C-I ions [26].
Although these peaks were detected on different Pro-
teinChip arrays (CM10 cation exchange surface), this
protein may also bind to the IMAC30 Ni-metal-affinity
surface. An extra argument is that besides m/z 3323, we
also detected the peak representing apolipoprotein C-I
itself in the current study (m/z 6637). Although its rela-
tionship with early stage breast cancer was not statisti-
cally significant (p = 0.23), the Z-log-transformed
intensities of m/z 6637 and m/z 3323 detected in the
current study were also correlated (Pearson R
2 = 0.558
(p < 0.001) in the controls), as expected between a pro-
tein and its doubly charged ion.
The peak with m/z 8938 is likely to be C3a des-argi-
nine anaphylatoxin (C3adesArg)( M W :8 9 3 9D a ) ,b a s e d
on a previous study by our group [27]. In that study a
peak with m/z 8937 was identified as C3adesArg by
protein purification and in-gel tryptic digestion, followed
by peptide mapping. The identity of the peak was con-
firmed by sequencing the tryptic digest peptides by
quadrupole-time-of-flight MS and by an immunoassay
on ProteinA beads [27].
Proteins detected with 2D-nanoLC-MS/MS
In total, 110 different proteins were detected in the sam-
ples of the 20 cases-control pairs with 2D-nanoLC-MS/
MS. For only 32 of the detected proteins, ratios and EF’s
could be calculated for at least 14 of the 20 case-control
pairs (Table 4). Afamin, apolipoprotein E and an iso-
form of inter-alpha trypsin inhibitor heavy chain H4
(ITIH4) were statistically significantly higher (p < 0.05)
in cases than in controls (weighted mean ratio: 1.10
(95%CI: 1.02-1.18), 1.13 (95%CI: 1.01-1.26) and 1.08
(95%CI: 1.03-1.14), respectively). Alpha-2-macroglobulin
and ceruloplasmin were statistically significantly lower
(p < 0.05) in cases than in controls (weighted mean
ratio: 0.94 (95%CI: 0.88-1.00) and 0.94 (95%CI: 0.89-
0.99), respectively). After correction for multiple testing
using the FDR, ITIH4 appeared to have less than 10%
chance to be a false positive finding.
Discussion
We found several proteins that showed different intensi-
ties in pre-diagnostic serum samples of breast cancer cases
not yet showing clinical symptoms compared to samples
of healthy controls. Two proteins detected with SELDI-
TOF MS, one with m/z 3323, which is likely to be a dou-
ble charged ion of apolipoprotein C-I, and another with
m/z 8938, which is likely to be C3adesArg, were found to be
related to pre-diagnostic breast cancer. Of the proteins
detected with 2D-nanoLC-MS/MS, afamin, apolipoprotein
E and an isoform of ITIH4 were slightly, but significantly
higher and alpha-2-macroglobulin and ceruloplasmin
slightly, but significantly lower in pre-diagnostic breast
cancer samples compared to control samples. Although
correction for multiple testing revealed that only ITIH4
had less than 10% chance to be a false positive finding,
several of the other proteins have previously been found in
relation with symptomatic breast cancer. M/z 3323, which
probably represents the double charged ion of apolipopro-
tein C-I, showed the largest difference between cases and
controls. Apolipoprotein C-I itself, detected both with
SELDI-TOF MS (m/z 6637) and 2D-nanoLC-MS/MS,
showed results in the same direction, i.e. higher in cases,
but not statistically significantly. In a study by Engwegen
et al. [26], examining serum samples taken after diagnosis,
the doubly charged ion of apolipoprotein C-I was lower in
breast cancer cases, but not statistically significantly. Apo-
lipoprotein C-I itself (6631 Da), was statistically signifi-
cantly lower in breast cancer cases in that study [26]. It is
striking that the same protein was found to be related
Table 3 The Z-log-transformed intensities of the peaks
detected with SELDI-TOF MS, ordered by their m/z
Cases
(n = 65)
Controls
(n = 65)
Paired
T test
M/z Mean
Z-log-
transformed
intensity (SD)
Mean
Z-log-
transformed
intensity (SD)
Intensity in
cases
vs. controls
p-
value
2958 0.06 (0.95) -0.03 (1.02) - .61
3323 0.21 (0.98) -0.19 (0.97) Higher .02
3888 0.12 (1.00) -0.13 (0.99) - .18
4649 0.03 (0.95) -0.02 (1.00) - .80
4824 -0.09 (0.85) 0.13 (1.11) - .21
5343 0.09 (0.87) -0.05 (1.08) - .43
5911 0.00 (0.76) 0.03 (1.16) - .86
6117 0.03 (0.90) -0.01 (1.06) - .81
6439 0.09 (0.99) -0.11 (1.01) - .27
6637 0.11 (0.97) -0.10 (1.03) - .23
6842 0.08 (1.01) -0.07 (1.00) - .43
6948 -0.12 (1.01) 0.14 (0.93) - .15
7476 -0.04 (0.94) 0.05 (1.06) - .62
7772 0.06 (0.95) -0.08 (1.05) - .45
7978 0.11 (0.97) -0.12 (1.02) - .21
8148 0.11 (0.97) -0.12 (1.02) - .21
8609 -0.04 (1.02) 0.07 (0.97) - .55
8938 0.19 (1.02) -0.14 (0.94) Higher .06
9294 0.03 (0.89) 0.00 (1.03) - .88
9427 0.15 (1.09) -0.17 (0.88) - .08
9501 0.06 (0.87) -0.05 (1.06) - .54
13892 -0.08 (0.97) 0.12 (0.95) - .26
M/z: mass-to-charge ratio; SD: standard deviation; -: No statistically significant
difference in intensity
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Page 7 of 11with breast cancer in both studies, but in different direc-
tions. This may be due to differences in sample collection,
processing and storage, but also to the differences in stage
of disease of the two study populations. We included sam-
ples collected up to three years before diagnosis, while in
the study by Engwegen et al. [26] samples were collected
after diagnosis. Apolipoprotein C-I may be differently
expressed in pre-diagnostic stages of breast cancer com-
pared to stages visible on a mammogram and/or leading
to clinical symptoms. It is also possible that the result is a
chance finding.
M/z 8938, probably representing C3adesArg,t h a tw e
found to be higher in pre-diagnostic breast cancer
samples, has been found to be related to breast cancer
in several previous SELDI-TOF MS studies
[2,3,6-8,28]. In the majority of these studies the pro-
tein was higher in patients compared to controls
[3,6-8], but in two studies it was lower [2,9]. ITIH4
was higher in our pre-diagnostic breast cancer sam-
ples than in the control samples. This is a protein of
which fragments have been frequently described in
relation to symptomatic and/or mammographically
detectable breast cancer [6-9,29-31]. In these studies
l e v e l so fa4 . 3k D aI T I H 4f r a g m e n tw e r ef o u n de i t h e r
to be significantly higher [7,30], or significantly lower
[6,8,9] in breast cancer. Levels of other fragments of
ITIH4, which were investigated by Villanueva et al.
[29], Song et al. [30], and our own group [31], were
usually found to be higher in breast cancer or were
not related at all [29,30].
Table 4 Proteins detected with 2D-nanoLC-MS/MS in 14 pairs or more
Pairs* Weighted ratio
† Random fixed
effects model
Protein Name Function n Mean 95%CI p-value
Vitronectin 16 1.06 0.99-1.13 .07
Transthyretin 15 0.98 0.88-1.09 .71
Alpha-1B-glycoprotein 20 1.03 0.99-1.07 .17
Alpha-2-macroglobulin Proteinase inhibitor 20 0.94 0.88-1.00 .04
Afamin Serum transport protein 17 1.10 1.02-1.18 .02
AMBP protein 18 1.04 0.97-1.12 .26
Apolipoprotein A-I 20 1.04 0.97-1.12 .25
Apolipoprotein A-II 20 0.98 0.91-1.06 .61
Apolipoprotein A-IV 20 1.05 0.95-1.18 .32
Apolipoprotein B-100 20 1.06 0.99-1.12 .08
Complement C3 (Fragment) 20 1.02 0.98-1.06 .34
Isoform 1 of Complement factor H 18 1.02 0.97-1.07 .39
Ceruloplasmin Acute phase reactant 20 0.94 0.89-0.99 .03
Hemopexin 20 0.96 0.90-1.02 .17
Histidine-rich glycoprotein 20 0.96 0.89-1.04 .30
Inter-alpha trypsin inhibitor heavy chain H1 16 1.00 0.94-1.07 .89
Alpha-1-acid glycoprotein 2 16 1.00 0.93-1.08 .91
Inter-alpha (Globulin) inhibitor H2 18 0.96 0.89-1.04 .33
Orosomucoid 1 20 1.06 0.98-1.14 .16
Alpha-1-antichymotrypsin 19 1.00 0.92-1.08 .94
B-factor, properdin 18 0.99 0.94-1.05 .76
Plasminogen 18 0.98 0.90-1.07 .69
Alpha-2-HS-glycoprotein 18 1.00 0.94-1.07 .88
Beta-2-glycoprotein 1 18 0.99 0.92-1.05 .66
C4B1 16 0.99 0.93-1.05 .74
Prothrombin (Fragment) 16 0.98 0.88-1.10 .76
Apolipoprotein E Lipid metabolism 16 1.13 1.01-1.26 .04
Apolipoprotein C-I 14 1.02 0.94-1.12 .57
13 kDa protein 14 1.03 0.92-1.16 .55
Isoform LMW of Kininogen-1 18 1.06 0.98-1.14 .13
Isoform 1 of inter-alpha trypsin inhibitor heavy chain H4 Acute phase reactant 16 1.08 1.03-1.14 <.01
Vitamin D-binding protein 20 1.03 0.99-1.07 .17
95%CI: 95% confidence interval; * Number of pairs in which a ratio could be determined and a EF could be calculated;
† Ratio case/control
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macroglobulin and ceruloplasmin have not been found
before to differ between breast cancer serum samples
and control serum samples in studies using SELDI-TOF
MS or other profiling methods. In the 1980s however,
the acute phase proteins alpha-2-macroglobulin and cer-
uloplasmin were already studied in relation to breast
cancer, using immunoassay methods [32,33]. Serum
levels of alpha-2-macroglobulin did not differ between
breast cancer patients and women with benign breast
disease [32]. In our study, alpha-2-macroglobulin and
ceruloplasmin were both lower in pre-diagnostic breast
cancer samples compared to the control samples.
It may be a limitation that we did not perform struc-
tural identification, and validation of the discriminative
power in an independent validation set, of the two dis-
criminative proteins detected with SELDI-TOF MS.
However, it is very likely that these proteins are acute
phase reactants, which are not cancer specific, let alone
breast cancer specific. Therefore, we decided not to
invest in structural identification and validation. More-
over, another similar study population was not available
for validation. Nevertheless, it is very interesting that
this kind of proteins is already discriminative up to
three years before the diagnosis of breast cancer. There-
fore, our results should not draw our attention to these
specific proteins, and their potential as breast cancer
biomarkers, but rather to the fact that an inflammatory
process is already measurable up to three years before
diagnosis, at a moment that only few tumor cells or a
very small tumor may be present.
The most important strength of our study is that we
investigated proteomic profiles in serum of patients with
asymptomatic breast cancer (diagnosed after a median
time of 21.3 months (IQR: 0.7-26.6) after enrollment).
Our study population therefore is more appropriate for
finding early breast cancer biomarkers than all previous
studies where mostly symptomatic cases were included.
The case-control design nested in a cohort of, appar-
ently healthy screening participants also ensures that all
serum samples were collected, processed and stored uni-
formly under strictly defined conditions, at a time when
none of the participants were diagnosed with breast can-
cer yet. These factors have shown to be important in
protein profiling studies [10-16]. In this way systematic
errors due to differences in these factors between cases
and controls were prevented in our study. Moreover, we
were able to control for many (possible) confounding
variables, by including only post-menopausal women,
who never had cancer before, were not diabetic, were
not current smokers, and did not currently use oral con-
traceptives or menopausal hormone therapy [20].
Furthermore, we could correct the results for age, BMI,
past oral contraceptive and HT use, number of children,
past smoking habits, alcohol intake, and several serum
sample characteristics.
A limitation of our study is that, due to the strict
selection criteria and the limited availability of pre-diag-
nostic serum samples of breast cancer cases, we were
only able to include 68 case-control pairs in our study.
Due to time and cost restriction, for the 2D-nanoLC-
MS/MS analysis we only included the 20 cases that
were diagnosed with breast cancer within the first 14
months after enrollment in the study, and their matched
controls. These samples sizes are limited, but the strict
selection criteria also prevented bias and confounding.
By measuring the protein profiles both with SELDI-
TOF MS and 2D-nanoLC-MS/MS we benefited of the
advantages of two complementary methods. SELDI-TOF
MS has the advantage to simultaneously measure parts
of the serum proteome in a high-throughput fashion
with relative simple sample preparation, high analytical
sensitivity and high speed of data acquisition [34,35].
Although with 2D-nanoLC-MS/MS fewer samples can
be measured simultaneously, this method has the advan-
tage that it can identify the detected proteins immedi-
ately. Moreover, the protein detection by these two
methods is complementary. With SELDI-TOF MS
mainly measuring proteins in the 2 to 10 kDa mass
range, many break-down products can be detected.
Additionally, by measuring exact mass-to-charge ratios
with SELDI-TOF MS, it is also possible to detect post-
translational modified forms of proteins; for example
proteins with additional amino acids or truncated forms.
With 2D-nanoLC-MS/MS in combination with iTRAQ-
labeling a higher selectivity is reached because of analy-
sis of tryptic peptides with protein identification based
on sequence information. This allows proteins with
higher mass to be identified which cannot be detected
with high sensitivity by SELDI-TOF MS.
Conclusions
We detected several serum proteins that differed in con-
centration between women with asymptomatic breast
cancer and matched healthy controls. For some of the
proteins this may have been a chance finding, but C3ade-
sArg and ITIH4 have previously also been found in rela-
tion with symptomatic breast cancer. Remarkably, high
abundant, acute phase proteins, which we expected only
to be detectable in symptomatic cancer cases, were also
found to be significantly higher before diagnosis. Given
that the currently identified proteins are high abundant,
they are unlikely to be breast cancer specific, at least on
their own. The fact however, that inflammatory pro-
cesses are already present up to three years before diag-
nosis needs to be further investigated. For the search for
specific tumor markers, we should take into account
that these are low abundant, as it is typical for known
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Page 9 of 11circulating tumor markers to have low concentrations
[36]. Using techniques that give insight into ‘the deeper/
low abundant proteome’,e . g .b yf r a c t i o n a t i o no ft h e
samples or depletion of a higher number of the most
abundant proteins, which was already partially done in
the 2Dnano-LC-MS/MS analysis, may help to find these
low abundant and probably more specific tumor
markers.
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